[1] |
HUANG Xiaoming, DU Ye, LIN Shaoming, SHEN Guanle.
Exploratory study of the influence of respiratory microbiology on the efficacy of PD-1 inhibitors monotherapy for patients with advanced non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 66-74.
|
[2] |
PEI Qinghua, SUN Jianli.
Research progress of Osimertinib acquired resistance
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 105-112.
|
[3] |
WEI Weitian, CHEN Sheng, WANG Liang, ZENG Jian.
Breviscapine induced the apoptosis of non-small cell lung cancer A549 cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 618-624.
|
[4] |
WANG Haili, GONG Tianxiao, ZHOU Shixia, MEI Jiazhuan, ZHANG Zhongmian.
Efficacy and safety of third-line treatment with mesylate apatinib in patients with advanced non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 567-572.
|
[5] |
YANG Ke, LI Junling, DU Bin, TIAN Zhongqiu, JING Xiujuan.
Single-arm,one-center, exploratory clinical trial of albumin-bound paclitaxel second and more line therapy for advanced non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1281-1286.
|
[6] |
WANG Haixia, LIU Xingan, HOU Jiyuan, GONG Zhe, SHAN Guoyong.
Influence of genetic variation of KDR on clinical outcomes of advanced NSCLC treated by first line bevacizumab regimens
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 802-808.
|
[7] |
LI Weiwen, LI Yuan, SUN Lei, HUANG Gongcai, ZHAO Zhongwei.
Synergistic effect of Addie injection on pemetrexed combined with nedaplatin in the treatment of advanced non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 325-328.
|
[8] |
BAO Zhi-jian, CHEN Dao-bao, LI Bo-ying.
Research on the therapeutic effect and adverse reactions of combination chemotherapy with NVB and TXT on non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(8): 916-919.
|
[9] |
PENG Ye, WANG Mei-qin, XIE Na, LI Yan, LU Hai-yan, LI Bing-mao.
Randomized study of thalidomide in combination with TP chemotherapy for the treatment of advanced non-small-cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(3): 317-321.
|
[10] |
CHEN Dong-yun, ZHAO Wen-ying, JI Zhao-ning.
Clinical study comparing pemetrexed plus carboplatin with gemcitabine plus carboplatin as first-line treatment in patients with advanced nonsquamous non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(12): 1401-1405.
|
[11] |
XU Feng-hua, GUO Rong-rong, LI Xin, LONG Li-yan, ZHANG Gui-yun.
Relationship between ERCC1 expression and sensitivity of platinum-based chemotherapy in NSCLC: a systematic review
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(1): 45-50.
|
[12] |
ZHAO Wen-ying, CHEN Dong-yun, CHEN Jing-hua.
Observation of short-term therapeutic and adverse effect of lentinan and gemcitabine plus cisplatin as the first-line treatment for advanced non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(1): 71-77.
|
[13] |
HUA Zhi-hui, FANG Wen-zheng, ZHAO Zhong-quan, XIE Fang-wei, OU YANG Xue-nong, SONG Hong-tao.
Association study of ERCC1 and ERCC4 genetic polymorphism with response and survival in non-small cell lung cancer patients treated with cisplatin-based chemotherapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(7): 772-778.
|
[14] |
LI Yan-hong, ZHU Huai-jun.
Paclitaxel in treating non-small cell lung cancer: A systematic review
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(1): 74-81.
|
[15] |
ZHAO Wen-ying, JI Zhao-ning.
Comparative study of cisplatin plus gemcitabine versus cisplatin plus vinorelbine in patients with advanced stage non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(12): 1408-1411.
|